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ABSTRACT
A great deal of evidence is accumulating that stress may affect cancer progression and patient
survival, yet the mechanisms for this association are poorly understood. Cortisol is the primary
stress hormone where several clinical studies have demonstrated that Cortisol levels positively
correlate with high mortality rate and recurrence of cancer. This study focuses on resolving the
mechanism of Cortisol in breast cancer initiation and progression. Our data demonstrates that
stimulation with Cortisol directly enhances breast cancer cell numbers and increases the rate that
cells exit from Gl phase of the cell cycle. Furthermore, we demonstrate that Cortisol enhances
breast cancer cell migration as measured by the ability to repair a wound as well as cell
migration towards a chemoattractant. Microarray analysis has revealed numerous interesting
targets for these effects. This approach to studying tumourigenesis may provide targets for drug
design that will improve current treatment strategies.
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INTRODUCTION:
Cortisol and Cancer: Clinical Evidence
A great deal of evidence is accumulating that stress and other behavioural factors
may affect cancer progression and patient survival. Cortisol measurements are thought to
be a dependable method in assessing an individual's physiological stress. However,
studies looking at social support surrounding the patient and levels of Cortisol remain
elusive among clinical data (Turner-Cobb, Sephton, Koopman, Blake-Mortimer, &
Spiegel, 2000).
It has been shown that as high as 70% of patients with breast cancer show
constantly high levels of Cortisol (Turner-Cobb et al, 2000). Several clinical studies have
demonstrated that Cortisol levels correlate positively with cancer severity (Abercrombie,
Giese-Davis, Sephton, Epel, Turner-Cobb, and Spiegel, 2004) and mortality rate and
recurrence of breast cancer (Sephton, Sapolsky, Kraemer, and Spiegel, 2000). Sephton et
al. (2000) reported that flatter slopes of Cortisol were linked to fatigue amongst breast
cancer patients and even predicted shorter life-span, and was completely independent of
other prognostic factors. Ambercrombie et al. (2004) studied women with metastatic
breast cancer and found similar results to Sephton et al. (2000) such that women with
metastatic breast cancer were more likely to show flatter Cortisol slopes compared to the
healthy control population. Ambercrombie et al. (2004) postulated that such
abnormalities could be a result of the Hypothalamic- Pituitary- Adrenal (HPA) feedback
system malfunction, hypersensitivity towards stress, inability to inactivate Cortisol, or
even sleep irregularities.
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Kagaya, Okamura, Takebayashir, Akechi, Morinobu, Yamawaki, & Uchitomi
(2003) studied psychological problems and Cortisol concentrations in patients with breast
cancer throughout their treatment. Participants were assessed for a variety of disorders
including, but not exclusive to depression-dejection, and tension-anxiety. Kagaya et al.
(2003) found 35% of participants had elevated Cortisol levels throughout the course of
their treatment, but this was not dependent upon the psychiatric disorders found within
group. Since the heightened levels of Cortisol did not appear to be correlated with the
psychiatric disorders, Kagaya et al. (2003) hypothesized that this was related to the breast
cancer

itself.
Chronic stress may result in a more sensitive HPA response to stress over-time.

Spiegel, Giese-Davis. Taylor, & Kraemer (2006) looked at the 'pathobiology' of specific
Cortisol concentrations taken throughout the day in women with metastatic breast cancer.
Spiegel et al. (2006) hypothesized that flatter Cortisol levels would be associated with an
inability to suppress Cortisol assessed through a dexamethasone (DEX) suppression test
hyperactivity of Adrenocorticotrophin Hormone (ACTH), as well as a higher sensitivir\
to stress. Participants included metastatic breast cancer patients undergoing treatment.
Cortisol was measured through saliva samples taken on 2 successive days at 5 specific
time points throughout the day. waking, 30 minutes after waking, noon, 5 and 9 pm.
Spiegel et al. (2006) found an increasing daytime Cortisol slope with increased Cortisol
concentrations 30 minutes post waking and this trend continued and was highly
associated with flatter Cortisol slopes throughout the day. Furthermore, participants who
had a higher level of Cortisol consistently throughout the day did not reveal changes
during the administered stress measures. Flatter day time Cortisol slopes were also
2

correlated with HPA failure to suppress Cortisol levels via the DEX suppression test
suggesting dysfunction of the negative feedback system within the HPA.
Turner-Cobb et al. (2000) predicted that the higher the quality and quantity of
social support given would be more correlated to normal endocrine levels of Cortisol. The
researchers hypothesized that a greater social network and better quahty of support would
correlate with lower Cortisol levels, and that greater social networks and quality of
support would correlate with a steeper diurnal slope of Cortisol. Participants with
metastatic breast cancer were assigned at random to either the psychosocial treatment or
the educational control group. All

participants were required to complete baseline

questionnaires that assess perceived social support, the quality of social support, as well
as measures assessing perceived available as well as quality of support prior to treatment.
Participants were asked to collect saliva samples at 8am, 12pm, 5pm, and 9pm on 3
successive days. Turner-Cobb et al. (2000) found a significant negative correlation with
positive appraisal, belonging, and support with respect to Cortisol levels. Turner-Cobb et
al., (2000) found no support for their hypothesis for slope of Cortisol with respect to
quantity, but did find statistical significance for quahty of support received. These results
are also comparable to other studies measuring other endocrine and immune responses
where social support was highly correlated with proper immune functioning (TurnerCobb et al, 2000).
Despite multiple studies consistently reporting similar findings, there are studies
that cannot replicate them or found different results altogether. Recently, Palesh, Butler,
Koopman, Giese-Davis, Carlson, & Spiegel (2007) suggested that women who have
-3-

endured stressful or traumatic events, or perceive these events to be particularly stressful
or traumatic in their lifetime have a decreased ability to resist tumour formation.
Although finding some significant difference in Cortisol levels when comparing cancer
patients and controls with respect to perceived psychological-social support, Palesh et al.
(2007) could not find any significant differences between participants who experienced or
perceived only stressful events compared to those who only experienced or perceived
traumatic ones. Because there were no differences found between traumatic and stressful
events and Cortisol levels, these results do not clearly link breast cancer and Cortisol.
Vedhara, Tuin stra, Miles, Sanderman, & Ranchor (2006) compared breast cancer
patients with healthy controls using 4 different indices that are widely used amongst the
scientific community: AUC&> AUC„ EPQR-S, and HADS in regards to studying breast
cancer and the possible role that Cortisol may or may not have. The first 2 are indices
highly used to measure Cortisol whereas the latter 2 are indices that are used to measure
distress. Participants were required to take numerous saliva samples at specific times on 2
successive days that were then analyzed for Cortisol levels using a variety of methods. It
was revealed that the reliability between measurements was very low, producing low
validity. Furthermore, Vadhera et al. (2006) could not find distinct differences when
comparing breast cancer patients to normal controls. Interestingly, Nunes, Rodriguez, da
Silva Hoffmann, Luz, Filho, Miller, & Bauer (2007) compared breast cancer patients
receiving 'radiotherapy' as well as receiving information and treatment for stress relief to
breast cancer patients only receiving "radiotherapy treatment. Within a 24 day period
Nunes et al. (2007) found that relaxation techniques helped to lower psychological
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problems such as stress, anxiety, and depression but found Cortisol levels to not be
dependent on such therapeutic aids.
Cortisol and Cancer: Clinical data limitations
Despite the advancement in clinical research, data remains controversial making
conclusions difficult to infer and producing low rehability between studies. The majority
of the problems in regards to clinical data in relation to support systems and Cortisol are
due to methodology. Variables such as how Cortisol samples were collected, the time of
day Cortisol levels were assessed at, what type of support was given, participant
differences, in addition to integrating compounding variables such as other medications
the patient may be taking all are contributing factors to why the data is not clear.
Additional caveats to the current in vivo clinical studies conducted on this topic include
time discrepancy allotted for testing; the majority of studies collect data for less than or
up to a year making it hard to generalize long-term information. There are also
confounding issues inherent to dealing with human populations; for support studies even
if participants receive identical support, the support given may not be perceived as such
by each individual. Many of the studies rely on the participants' ability to measure their
own Cortisol levels making researchers highly dependent on the participant's willingness,
accuracy and ability to accurately record data. Cortisol is also extremely tissue-specific
and can have various outcomes depending on where it is located within the body
(Ashwell, Lu, and Vacchio, 2000) making any specific conclusions to the role of Cortisol
in breast cancer very non-specific. It is therefore, extremely important to determine the
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cellular effects of Cortisol and to clearly resolve the underlying molecular mechanisms of
Cortisol in both normal breast growth and development as well as in breast tumorigenesis.
Physiological Role of Cortisol in a Healthy Individual:
The effects of Cortisol throughout the body range tremendously, many are
important for mamtaining homeostasis as well as preparing the organism to react and
manage physical and psychological stress. Stress can be defined as many things
including, but not exclusive to exercise, emotional disturbances, trauma, haemorrhage and
fever (Ashwell, Lu, & Vacchio, 2000). Cortisol promotes carbohydrate and protein
disassembly as well as exerts numerous, complicated effects on fat distribution as well as
breakdown. Cortisol is imperatively involved with immune and inflammatory processes;
which are crucial for many actions involved with body immune defence mechanisms. It is
within these defence mechanisms that it can be observed that Cortisol functions to protect
the host from stress whereby halting the pathophysiological responses that the body
undergoes in the event of tissue damage and inflammation. Cortisol, in healthy cells is an
anti-inflammatory causing apoptosis through the mitochrondrial pathway requiring Apaf1 and caspase-9. Cortisol is capable of indirectly increasing blood pressure by affecting
the tissue-sensitivity to catecholamines. Its synthesis also affects bone formation, and can
display both positive and negative effects on cellular proliferation and cell death. Other
effects consist of mood and behavioural changes; decrease/increase in food intake, body
temperature, sensitivity towards pain as well as problems with neuroendocrine
functioning (Buckingham, 2006).
Cortisol Synthesis:
-6-

Cortisol is the principal glucocorticoid in man. Cortisol is released into the blood
stream in a pulsatile nature and concentration increases or decreases; which is reflective
of the time of day. Cortisol levels are approximately 3-5 times higher in the early morning
hours prior to waking and are lowest early in the sleep cycle. These concentrations can
spike in a matter of moments in response to physical or psychological stress. This "stressresponse' will override the normal circadian function of Cortisol and will vary depending
on the severity and longevity of the stressor (Buckingham, 2006).
Cortisol synthesis first commences within the hypothalamus with the secretion of
corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) by the
parvocellular neurons within the paraventricular nucleus. Traveling through the
hypophyseal-portal blood vessels, CRH and AVP reach and bind to the type 1
corticotrophin-releasing hormone receptor and the type lb vasopressin receptor,
respectively,

of the

anterior

pituitary

gland.

This

causes

the

release

of

adrenocorticotrophic hormone (ACTH) from the corticotrophin producing cells into blood
circulation (Buckingham, 2006). ACTH circulates throughout the body and binds to type
2 melanocortin receptors which trigger the synthesis of corticosterone/cortisol within the
zona fasciculate of the adrenal gland (Buckingham, 2006). Cortisol synthesis begins with
the cleavage of the side chain of cholesterol by enzyme p450scc which creates
pregnenolone. Pregnenolone undergoes hydroxylation at carbon 17 by cytochrome
enzyme p450cl7, leading to 2 potential pathways for Cortisol synthesis: the inactive form
cortisone, and the active form Cortisol. Within the endoplasmic reticulum, pregnenolone
undergoes another hydroxylation by cytochrome enzyme p450c21 creating 11deoxycorticosterone, the inactive form of Cortisol. 11-deoxycorticosterone is converted
7-

into active Cortisol by p450cl 1 within the mitochondria (Ashwell et al., 2000). Because
Cortisol is lipophilic, it diffuses instantaneously through diffusion into the blood stream as
part of a protein complex consisting of the high-capacity, but low affinity protein albumin
as well as the low-capacity high affinity protein, corticosteroid-binding globulin (CBG)
(Ashwell et ah, 2000). This in turn, acts as a negative feedback system whereby Cortisol,
once in the bloodstream, reaches the hypothalamus and pituitary glands and suppresses
the production of CRH, AVP, and ACTH. The sensitivity of this negative feedback
system is extremely dependent on the levels of Cortisol already present in the bloodstream
(Buckingham, 2006).
Ninety-five percent of Cortisol in the bloodstream is bound to CBG and the
remaining 5% of 'free Cortisol' is able to diffuse through the membrane to exert cortisolmediated effects. The amount of free Cortisol capable of binding to the glucocorticoid
receptor (GR) at any given time in a healthy individual ranges from 0.5-1 nM, but can
decrease approximately 20-30% within the early stages of sleep. However, in cases of
intense physical stress, such as inflamed tissue, local serine proteases are capable of
releasing the bound Cortisol from the CBG, thereby increasing free Cortisol levels, in
some cases this is found to exceed levels higher than 50 uM (Buckingham, 2006).
Variations in Cortisol secretion depend on concentrations already present within the
bloodstream, the time of day, and any perceived stressors occurring, either physical and
or psychological. Cortisol levels over the course of the day ranges anywhere from 3 to 10
times higher the basal concentration (Ashwell et al., 2000).
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To date, 2 unique isoforms lip-hydroxysteroid dehydrogenase (HSD), with
differing actions have been found: HSD type 1 and HSD- type 2. Type 2 is found to be
co-expressed with the mineralcorticoid receptor (MR) in the kidneys, parotid and sweat
glands, as well as smooth muscle tissue. It has also been found within the developing
brain as well as the placenta, and is thought to act as a protective agent against the
possibly harmful effects of Cortisol surplus (Buckingham, 2006). lip-HSDl's role is to
stimulate inactive cortisone to its active counterpart, Cortisol. lip-HSDl is found
predominately within the liver, adipose tissues and its regulation is sensitive to numerous
factors including Cortisol, stress, and cytokines. It has been shown to be capable of
bidirectional function in vitro acting as both a dehydrogenase and reductase
(Buckingham, 2006). lip-HSDl is found where the GR is abundant, but it demonstrates
low affinity for Cortisol. It has been suggested that this reflects that the main role of 1 ipHSD1 is to generate and increase the local amount of 'free Cortisol' where Cortisol is
critical in endocrine functioning (Buckingham, 2006). The number of GR present within
normal and cancerous breast tissue is extremely correlated with the enzyme 11P-HSD1.
Steroid Receptor Family
There are 48 members within the nuclear receptor superfamily. Within this family
are many sub-groups. Members of the steroid superfamily include the GR, MR,
progesterone receptor (PR), 2 oestrogen receptors (ER), and androgen receptor (AR)
(Faus and Haendler, 2006). All steroid receptors share common characteristics such as a
highly conserved centrally localized zinc-finger DNA binding domain (DBD). a less
conserved carboxyl-terminal ligand binding domain (LBD) (Heitzer, Wolf, Sanchez,
-9-

Witchel, & DeFranco, 2007). The amino terminal domain (NTD) differs between steroid
receptors except to the abundant negatively charged acidic amino acids. This region is
often referred to as the activation function 1 (AF-1) and functions in transcriptional
regulation that is not necessarily independent of ligand binding (Heitzer et al.. 2007).
GR Gene and Protein Structure:
The GR gene contains 9 exons capable of alternative splicing, which allows for
variations of the GR to be observed. The isoforms most commonly studied, due to their
relative abundance, are GRa, and GRP (Lu and Cidlowski, 2006). These isoforms differ
in their C-terminal region beginning at amino acid 727 where GRa has an additional 50
amino acids, but GRP only has 15. these residues share no apparent identity. It is known
that glucocorticoids predominately arbitrate their effects via the GRa. The GRa protein is
a single 777 amino- acid structure that resides within the cytoplasm of the cell bound to
heat shock proteins (hsps) 90, 70. 50, and 20 (Buckingham, 2006). This maintains the
integrity of the GR by facilitating proper folding as well as preventing the GR from
binding to the glucocorticoid regulatory elements (GREs) in the absence of Cortisol
(Heitzer et al., 2007) GRs can be found in almost every cell type within the human body,
and comprise an approximate 200 to 30, 000 per cell where the affinity for Cortisol around
30nM (Adcock, Caramori, and Ito, 2006). The GR is divided into 4 distinct sections as
illustrated

below:

NTD

DBD H

LBP

k

(Heitzer et al, 2007)
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The N-terminal AF-1 region, containing imperative transactivational functions.
This region has been shown to interact directly with basal transcriptional machinery as
well as other cofactors that contribute in transcriptional regulation; moreover, interference
of AF-1 decreases reporter gene expression (Heitzer et al.. 2007). There is also an
important DNA binding domain (DBD) comprised of 2 zinc fingers and a hinge region
housing the nuclear localization signal as well as the ligand binding domain (LBD) with
supplementary transactivation functions. The LBD, also known as AF-2, constitutes 12
alpha-helices that go through broad conformation changes post ligand binding (Faus and
Haendler, 2006). The LBD remains hidden within the GR while it is associated with
hsp90, and contains sequences for protein-protein interaction with hsp90. Unlike AF-1,
AF-2 is completely dependent on glucocorticoid binding; which allows AF-2 to undergo a
conformational change enabling co-activators or co-repressors to contribute in
transcriptional activation. Furthermore, AF-2 can act in unison with AF-1 to facilitate
transcriptional activity (Heitzer et al., 2007).
The most impressive structure within the GR is the C-terminal a-helix, which
folds over enclosing the hydrophobic pocket where the ligand has bound. This folding
allows for cofactors to recognize the active GR complex which is essential for
transcription machinery to be recruited for the activation of target genes (Faus and
Haendler, 2006).
As referred to above, it is this region that differs between GRa and GRJ3. Due to
these differences, GRa is activated via ligand binding while GR|3 is not capable of hgand
binding, hence glucocorticoids demonstrate their effects through the GRa (Moutsatsou
11

and Papavassiliou, 2008). In addition to differences in the mechanism of activation
between these two receptor subtypes, these receptors are distributed differently. Both are
expressed throughout the body, but GRa is expressed at high levels while GRP is
expressed at very low levels. QRT-PCR as well as western blot examination revealed
that it is the GRa, and not GRP that is expressed in the breast (Moutsatsou and
Papavassiliou,

2008).

GR Signalling:
Glucocorticoids bind to the GR via passive diffusion through the cellular
membrane due to their 'lipophilicity', however, it has been reported that even
glucocorticoids might actually use a membrane transporter in order to move into the
cytoplasm of the cell (Tasker, Di, Malcher-Lopes, 2006). The GR is reliant on 3 factors
that are essential for GR activation: the amount of Cortisol available for binding, the
receptor, as well as the recruitment of other transcription factors and proteins.
Functioning as a monomer, the GR can bind and inhibit proinflammatory transcription
factors (TFs) such as NF-kB and AP-1, nongenomically (Adcock et ah, 2006). As a
homodimer, the GR complex is capable of shuttling into the nucleus and binding to the
specific DNA elements, GREs within the promoter regions specific to proinflammatory
gene targets thereby blocking gene expression.
Genomic activity of the GR requires a "conformational change' upon binding
Cortisol whereby the hsps are removed (Moutsatsou and Papavassiliou, 2008). In addition
to binding GRE elements directly, the active GR complex can also associate and interact
with other DNA bound transcription factors to regulate transcriptional effects (Heitzer et
12-

al., 2007). A proper GR-DNA complex with other proteins regulates the communication
of other co-activator complexes on specific GR target promoters. The GR cannot recruit
all cofactors that are necessary around the target promoters, but with the aid of steroid
coactivators that are recruited by the GR, this enables the recruitment of other
coactivators as well as chromatin remodelling complexes to form the transcription
initiation complex allowing for local chromatin remodelling (Ito, Chung, & Adcock,
2006).
GR-GRE recruitment can result in an increase or a decrease of GRE-dependent
gene transcription (Moutsatsou and Papavassiliou, 2008). Furthermore, corticosteroid
binding to the GR transcriptionally activates the expression of ribonucleases as well
mRNA destabilizing proteins which target anti-inflammatory genes, thereby indirectly
regulating the expression of genes. From a therapeutic standpoint however, the most well
studied action of the glucocorticoids is to repress the transcription of cytokines and
chemokine genes implemented in inflammation (Adcock et al., 2006). GR activation also
results in activation of many genes implicated in metabolic homeostasis such as raising
blood glucose levels, gluconeogenesis, as well as the recruitment of amino and fatty acids
(Heitzer et al, 2007).
GR and Receptor Cross-talk
Evidence has shown that GR signalling engages in considerable cross-talk and
promiscuity between the other steroid receptors, oestrogen and progesterone.
Glucocorticoids and progestins bind to their specific receptor, however, Fryer, Nordeen,
& Archer (1998) demonstrated that anti-progestins which inhibit the cell from utilizing or
-13-

synthesizing progesterone, inhibited GR-mediated transcription in breast cancer cells.
Furthermore, Wan and Nordeen (2003) revealed that glucocorticoid- like effects of
progesterone have been shown in some tissues, while progesterone-like effects of
glucocorticoids in other tissues have also been observed (Moutsatsou & Papavassiliou,
2008). Breast cancer cells expressing PR, but not the GR were utilized to demonstrate that
Cortisol mimicked the effects of progesterone by significantly inhibiting growth, cell
spreading and focal adhesions (Leo, Guo, Woon, Aw, and Lin, 2004). In contrast. PRnegative but GR-positive breast cancer cells, DEX, a synthetic of Cortisol, resulted in an
increase of focal adhesion and cellular proliferation (Moutsatsou & Papavassiliou, 2008).
Given that GCs and progestins are used in breast cancer treatment strategies, having a
clear understanding of the molecular biology mediating these effects in both PR-positive
and PR-negative breast cancers is essential.
As mentioned above, GR can interact with NF-kB nongenomically: this may play
an essential role in mediating the effects of GR in breast cancer cells. NF-kB becomes
activated through TNF-a, which increases gene transcription of anti-apoptotic properties,
but this may lead to cell sensitivity of TNF-a induced cellular death. TNF-a can activate
both apoptosis as well as cell survival depending on signalling activation (Moutsatsou &
Papavassiliou, 2008). Ozes, Mayo, Gustin, Pfeffer, and Donner (1999) have shown that
an activated NF-kB through cellular survival genes PI3K or Akt suppress TNF-a induced
cellular death in the human breast cancer cell line, MCF7. The importance of GR
interactions with NF-kB in breast cancer cells is not well explored.
Cortisol and Cell Cycle Progression
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GR-signalling exerts many effects including: cell growth arrest, apoptosis, as well
as differentiation to name a few. The underlying mechanisms involving these effects are
of high interest to the research field. Cell division occurs through 2 general stages: DNA
replication (S phase) and division of the replicated DNA into 2 daughter cells (mitosis; M
phase). Before DNA replication can occur there are growth phases the cell must go
through in order to ensure that the cell has sufficient nutrients and is without damage
prior to proceeding into S phase, this is referred to as

Gap 1 (Gl) of the cell cycle

(Vermeulen, Bockstaele, and Berneman, 2003). Cells are in this phase of the cell cycle
for the longest period of time, and the majority of all asynchronous cells will be found at
this stage. Should the environment be inadequate to support DNA synthesis the cell will
enter a resting state, referred to as GO or quiescence, where it will remain until conditions
are favourable. However, if conditions are favourable and the cell commits to DNA
replication, thereby passing a Gl-S restriction point, the cell cannot enter GO at this stage
and DNA synthesis will ensue. Following completion of S phase the cell enters Gap2
(G2) of the cell cycle, a stage where the cell prepares for mitosis and ensures that DNA
synthesis has been successfully completed without error prior to entry into mitosis
(Vermeulen et al., 2003). These phase transitions are controlled by important catalytic
proteins known as cyclin-dependent kinases (CDKs), which are ubiquitously expressed
but are activated at specific times during the cell cycle to transition a cell through each
specific phase. A total of 9 CDKs are known, but only 4 are characterized to function as
described to regulate the cell cycle: CDK 2, 4 and 6 function during Gl; CDK2 is also
functional during S phase, and CDK1 is the sole CDK regulating movement through G2
and M phase in mammals. The regulatory proteins that activate CDKs during specific cell
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cycle phases have been coined cyclins. Cyclin Dl, 2, and 3 bind to both CDK4 and 6
allowing the cell to enter into Gl. Cyclin D is a unique cyclin in that the protein levels do
not rise and fall with the cell cycle instead it is synthesized when growth factors are
present. Cyclin E binds to CDK2 which allows the cell to transition from Gl into S
phase; it is within this phase that cyclin A binds to CDK2, and is required for the cell to
successfully transition into G2. It is within the end of G2 phase and the beginning of the
M phase where cyclin A binds to CDK1 to trigger the cell into M phase. Mitosis proceeds
with the binding of cyclin B to CDK1 and movement of this complex into the nucleus to
phosphorylate substrates required for the stages of mitosis and cytokinesis (Vermeulen et
ah, 2003).
CDK function can be inhibited by proteins known as CDK inhibitors (CKI) that
bind either to the CDK directly, rendering the CDK incapable of interacting with its
specific cyclin, or they bind to the CDK-cyclin complex resulting in inactivation of the
complex (Vermeulen et al., 2003). These inhibitors are classified into 2 primary families:
the INK4 and Cip/Kip families. The INK4 family consists of plS 1 ^ 4 8 , 16™^, IS™40,
and i*) 1 ^ 40 that target inactivation of CDK4 and 6 preventing cyclin D binding within the
Gl phase of the cell cycle. The Cip/Kip family consists of p21cn>1, 27KIP1, and 57Kn>2 that
target inactivation of CDK-cyclin complexes. Hsu and Defranco (1995) have inferred that
GR signalling might be involved in cell cycle regulation. The researchers found that GR
signalling stimulated transition from Gl through S phase and they postulated that the cell
cycle is more sensitive to glucocorticoids in Gl/S than any other phase of the cell cycle.
However, Abel, Wochnik, Ruegg, Holsboer and Rein (2002) have suggested that GR
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signalling is indeed fully operational throughout the entire cell cycle, however due to
chromatin condensation GR signalling becomes repressed within G2/M phase.
Cortisol and Microarray Analysis
The invention of the microarray has revealed some remarkable and abundant genes
that are regulated by glucocorticoids (Buckingham, 2006). However, the use of
microarrays has created many new questions, and has answered few. As expected,
microarray studies have targeted genes involved in inflammation, immunity, cellular
proliferation, cellular death, differentiation, as well as endocrine function (Buckingham,
2006). Interestingly, there are numerous genes that cannot be placed within these
categories or their function is still unknown. Adding a further complication, microarray
studies have also revealed that different cells types, differences in Cortisol concentration
and formulation and timing of delivery all reveal differences in the regulated genes
(Buckingham, 2006). Kauppi, Jakob, Famegardh, et al. (2003) utilized a microarray with
a lung epithelial cell line treated with DEX and in the presence of cyclohexamide to
isolate genes transcriptionally regulated by Cortisol. This study demonstrated that DEX
can up-regulate 108 genes as well as downregulating 73 after only 6 hours treatment.
Many of the other regulated genes were categorized under proliferation, apoptosis,
inflammation, as well as surfactant synthesis. At the very least, microarray studies have
demonstrated how remarkable and complex the system of glucocorticoid action truly is;
with the ability to orchestrate a wide range of control through the physiological as well as
the pathological system (Buckingham, 2006).
Normal Breast Development; Links to Carcinogenesis.
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The mammary gland is a unique organ in that it undergoes the majority of
development post-embryonically. At puberty (approximately day 21 in the mouse) the
adult mammary stem cells undergo a burst of proliferation, as well as degrading of the
extra cellular matrix (ECM) to form the rudimentary ductal tree. Surges of hormones at
the onset of pregnancy induce yet another wave of proliferation to establish the alveolar
epithelium necessary to produce milk proteins during lactation. Mid-pregnancy,
approximately day 10 pregnancy, the gland begins preparing to undergo functional
differentiation by altering the morphology of the gland as well as initiating gene
expression necessary to synthesize milk proteins. Upon the birth of the pups the gland
ceases to proliferate and the alveoli begin to secrete milk. Genes regulating proliferation
represent potential targets that may be aberrantly regulated in breast cancer to support
uncontrolled proliferation. Similarly, genes regulating differentiation might represent
tumour suppressor genes that may be mutated or down-regulated in carcinogenesis.
Indeed, understanding normal breast development has revealed critical regulators of
specific forms of breast cancer such as c-Myc (Butt, Caldon, McNeil, Swarbrick,
Musgrove, & Sutherland, 2008), ras (McCubrey, Steelman, Chappell, Abrams, Wong ,
Chang, Lehmann, Terrian, Milella, Tafuri, Stivala, Libra, Basecke, Evangelisti, Martelli,
& Franklin, 2007)

and ErbB2/Neu (Murphy, Millar , & Lee, 2005). It is known that

abnormal morphology of the ECM is highly prevalent in metastatic breast cancers (Lee,
Hwang, Mead, and Ip, 2001).
Little is known about Cortisol and normal breast development. The literature
suggests that glucocorticoids promote expression of lactating proteins, casein and
lactalbumin (Ono and Oka, 1980). Interestingly, looking at lip-HSD, the enzyme
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responsible for inactivating glucocorticoids, levels were high in both virgin and pregnant
rat mammary cells, but lip-HSD ability to inactivate glucocorticoids was decreased by
75% during lactation (Quirk, Slattery, and Funder, 1990). It has also been shown that
Cortisol promotes morphology changes in the normal mammary epithelial cells (MECs)
such as 'alveolar and multilobular branching' (Darcy, et al., 1995). The essential GRresponsive genes responding to Cortisol during normal development have not been
isolated.
Cortisol and Breast Cancer: Molecular Evidence
The GR has been found in a large number of primary human breast cancers.
Abberant GR expression is seen in breast cancer stroma, particularly at more serious
stages of tumour development (Moutsatsou and Papavassiliou, 2008). Lien et al., (2006)
looked at GR expression levels using immunohistochemistry in 400 human breast tissue
samples ranging from normal tissue, to invasive lesions. Studies indicate that
approximately 20% of breast cancer profiles show the primary cause is due to mutations
in BRCA1 and 2, TP53, PTEN, and ATM (Rosman, Kaklamani, Pasche, 2007) with an
additional number of genes contributing to the overall survival of the patient (Oldenburg,
Meijers-Heijboer, Cornelisse, Devilee, 2007). Psychosocial as well as psychological
stress have also been correlated as causative factors (Bleiker and van der Ploeg, 1999).
Previous work performed by Holden, Pakula, & Mooney (1998) revealed prolonged stress
increased the amount of TNF in a variety of organ carcinomas. Another theory has been
suggested whereby stress increases the chance of breast cancer as well as the chance of
overcoming this disease by decreasing the ability of a cell to respond to DNA damage or
to even apoptose. Numerous studies in mice as well as humans reveal significant
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differences in a cell's ability to repair DNA damage or to undergo apoptosis while under
stress compared to cells not under stressful conditions (Glaser, Thorn, Tarr. KiecoitGlaser, D'Ambrosio, 1985; Fischman, Pero, & Kelly, 1996; Cohen, Marshall, Cheng,
Agarwal, Wei, 2000; Amsterdam and Sasson, 2002). To date, there is no model put forth
that explains these findings. It is possible to consider a model where Cortisol may change
the ability of proteins that are responsible and pivotal in DNA repair and apoptosis to be
hindered. Antonova and Mueller (2008) revealed that BRCA1 within the mouse healthy
mammary gland cell line, EPH4, was down-regulated by cortisone, the active form of
Cortisol (270nM). These authors suggest that these observations could shed light on a
molecular pathway for experimental manipulation to study possible alterations in DNA
repair mechanisms and cell survival during stressful times. By enabling the tumour
suppressor role of BRCA1, cortisone may affect the ability of cells to preserve genomic
stability and may even assist the cells' alterations to reveal carcinogenic properties.
Previous reports have shown that expression levels of BRCA1 increase during cellular
proliferation in the mammary gland (Gudas, Li, Nguyen, Jensen, Rauscher, Cowon, 1996)
Antonova and Mueller (2008) were curious if cell proliferation hinders the normal
repressive effects of cortisone on BRCA1 promoter activity and found that cortisone
treated cells completely repressed the BRCA1 promoter. It is also known that oestrogen
enhances the BRCA1 expression in proliferating cells (Romagnolo, Annab, Thompson,
Risinger, Terry, Barrett, & Afshari, 1998). To establish whether oestrogen-induced
BRCA1 expression prevents the repressive capabilities of cortisone, Antonova and
Mueller (2008) treated EPH4-L6 cells with lOnM oestrogen with and without cortisone at
a concentration of lug/mL. Predictably, oestrogen increased expression of BRCA1
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promoter without cortisone. With the addition of cortisone, the BRCAl promoter was
repressed despite oestrogen treatment. This group concluded that cortisone can abolish
the promoter activity of BRCAl by oestrogen.
This Masters project focuses on the underlying molecular mechanisms of
Cortisol's potential role in breast cancer initiation and progression. Given all clinical and
molecular evidence described we hypothesized that Cortisol functions through the
glucocorticoid receptor to mediate effects on cell growth, adhesion and migration
properties in both normal and cancerous breast cells. Specific aims of this project were to
determine the effects of Cortisol on cell proliferation, as well as migration and invasion, in
a panel of cancerous and normal breast cells and to evaluate the pathway of Cortisol's
mediated function in invasive breast cancerous cell lines.

METHODOLOGY:
Cell Culture.
Human mammary breast cancer cells, MCF7 ( gift from Tiffany Seagroves, U. of
Tennessee), HTB-26 and HTB-132 (graciously donated by Cindy Zahnow, John
Hopkins), normal mouse epithelial cells, HC11 (graciously donated by Carrie Shermanko,
U. of Calgary), and normal human breast cells HTB-125 (ATCC) were maintained in
RMPI-1640 medium (Sigma) or Dulbecco's Modified Medium (DMEM) (HTB-125,
HTB-26, -132) containing 2mM L-glutamine (Sigma), penicillin (Invitrogen),
streptomycin (Invitrogen) and were cultured in a 5% CO2, 37°C environment. MCF7 cells
were supplemented with 10% (vol/vol) new born calf serum (Sigma) and HTB-26, HTB132, HC11, HTB-125 cells were supplemented with 10% fetal bovine serum. HC11 cells
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were supplemented with lOng/mL epidermal growth factor (Invitrogen). Additionally,
HCll cells were supplemented with 5ug/ml insulin (Sigma). Normal human breast cell
line MCF-10A (graciously donated by Tiffany Seagroves, U of Tennessee) were
maintained in DMEM/F12 medium supplemented with 5% horse serum, lOug/mL
hydrocortisone, lOug/mL insulin, 20ng/mL epidermal growth factor. Receptor status for
MCF7, HCll and MCF-10A GR, ER, and PR positive. Cell lines HTB-26,HTB-132, and
HTB-125 are ER negative, GR and PR positive.
Reagents.
Hydrocortisone, 98% (Cortisol, Sigma) was dissolved in Dimethyl sulfoxide,
99.5% (DMSO, Sigma) at 0.362g/10mls for stock solution. Further dilutions included a
1:1000 ratio stock to cell culture media to obtain working experimental concentrations
within the range of Cortisol levels observed from in vivo data. Experimental control,
DMSO, was used per volume comparison for Cortisol.
Tamoxifen (TAM, Sigma) stock solution was previously dissolved to a 10 mM
concentration, and diluted to obtain various experimental concentrations. Mifepristone
minimum, 98% (RU486, Sigma) was dissolved into a 1M stock solution at 0.42959g/l ml
DMSO. Trypan Blue Solution 0.4% (Sigma # T8154) was used for proliferation assays.
Thiazolyl Blue Tetrazolium Bromide (MTT), 98% (Sigma #M2128) was dissolved in
PBS at 5mg/mL and used in proliferation assays. Extraction buffer for MTT consisted of
50mL N, N- Dimethylformamide, 99% (Sigma), lOg of Sodium Dodecyl Sulfate (SDS),
2.5mL glacial acetic acid, 2.5mL HC1, 30mL H20, adjusted to ph of 7.4.
Cell Proliferation.
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Cells were removed via trypsinization, and a 50 uL sample of cells was diluted 1:2 using
a Trypan Blue stock solution. A Bright-Line hemacytometer (Fisher Scientific) was used
to obtain an estimated average of available amount of cells present. Calculation for
estimated number of cells used is: # of cells counted/ 4 = XX. (XX)(2 xlOA4)(# mL used
to remove cells) (Peraino and Eisler. 1973). A total of 3 separate samples from each cell
line utilized were counted to ensure highest accuracy, and an average from these 3
separate counts was used in calculating cellular numbers per ml of media for the
experimental plates. Cells were plated at 4x10A6 per 3ml of serum-filled media per 60mm
tissue-culture plate, and allowed to adhere to ensure normal cellular function. Cortisol
was added 24 hours post-seeding with dose concentrations ranging from 0.1 uM to 80
uM. A DMSO vehicle control was utilized using the highest ul volume, and a no
treatment control was also incorporated. Experimental plates were incubated and cells
were trypsinized at specific time points 0, 2, 4, 6, 12, and 24 hr post-treatment. To obtain
statistical data each treatment rendered 3 experimental plates (N= 108). Upon
trypsinization, cells were collected and 3 samples from each experimental plate were
counted using a blind control with a hemacytometer in triplicate fashion for each time
point (N= 54). Tetrazolium Assay (MTT assay) was utilized as a control from the trypan
blue exclusion assay. Cells were removed and counted as explained above, and place into
a 96 well plate at 5 xlOA4 per well. Cells were allowed to adhere to ensure normal
cellular functioning. Cortisol was added 24 hours post-seeding with dose concentrations
ranging from 0.1 uM to 80 uM. A DMSO vehicle control was utilized using the highest
ul volume, and a no treatment control was also incorporated. Each dose was performed in
triplicate for statistical analysis. Experimental wells were incubated where 20uL/well of
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MTT was added and allowed to incubate for 4 hours at 37°C. Following MTT incubation,
100 uL extraction buffer was added to each experimental wells, wrapped in tin foil and
allowed to incubate at 37°C over-night. Data was quantified using the Victor 1420 Multilabel

Counter

(Perkin

Elmer)

using

a

590

nm

wavelength

filter

set.

Migration and Wound healing Assays.
HTB-26 and HCll cells were removed via trypsinization, counted as described
previously, and suspended in a l x l O ^ cellular solution. Migration was assessed using the
Cell Migration Assay Cytoselect 24 well (8 urn, Colorimetric) (Cell Biolabs, Inc.)
following the protocol suggested by the manufacturer with a 24 hr incubation time. Data
was quantified using the Victor3 1420 Multi-label Counter (Perkin Elmer) using a 590nm
wavelength filter set.
Wound healing assays were performed where HTB-26 and HCll cells were
grown to confluence on gridded tissue culture plates. Wounds were created with the aid
of a pipette tip scratched against the surface. Cortisol at various concentrations or the
appropriate DMSO control was added and cells were allowed to incubate for 24 hours.
Observations were recorded using the microscope software minisee 1.0.9.37 (Scoptek) in
addition to being quantified with the counting of open grids at various time points, 0, 3, 6,
12, and 24 hours.
Synchronization and Cell Cycle Analysis.
MCF7 cells were trypsinized from culture plates, and counted as described previously.
Cells were plated at 8x10A4 per 10cm tissue-culture plate and allowed a 24 hr time period
for adherence followed by serum-starvation for 24 hours to synchronize the cell
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population in GO. Following release into serum media containing 70 ng nocodazole and
either 40 uM Cortisol or DMSO control, cells were specific time points, 0, 2, 4, 6, 12, and
24 hours. At each time point 100 ul of a 1 mL collected sample was added to 400 ul of
cold PBS and 50 uL of a 500 mg/mL propidium iodide stock solution and placed into
glass cuvettes for cell cycle analysis via flow cytometry. Data was collected using a
Beckman Coulter FC500 (Biology Dept.; U of Windsor) and cell cycle profiles were
analyzed

using

CPX

Beckman

Coulter

FC500

software.

Receptor Inhibition Assay.
MCF7 cells were trypsinized, counted and plated, as described above, onto a 6 well tissue
culture plate at 1 x 10^5 per 1.5 mis of media per well and allowed 24 hr to adhere.
Various concentrations and combinations of Tamoxifen and RU486 were added to the
experimental wells in the presence of 40 uM Cortisol or a DMSO control to the MCF7
cell line and incubated for 12 hours. Cells were trypsinized and counted in triplicate for
statistical analysis. The receptor inhibition assay was performed in triplicate for statistical
analysis.
siRNA Transfection.
HTB-26 cells were trypsinized, counted and plated as described previously onto a 6-well
tissue culture plate at 2 x 10A5 per 2 mis of serum-filled media per well and allowed to
grow to 80% confluency. Transfection of HTB-26 cells were carried out using an
optimized protocol based on that previously outlined by Ehrhardt, Schmoke, Matzke,
Knoblauch, Will, Wixler, and Ludwig et al. (2006). In brief, the transfection reagent
Polyemylenimine (branched PEI) (Sigma-Aldrich; 408727) was used in solution at 1
-25-

mg/mL, neutralized with HCl, and sterile filtered. 10 uL of NaCl (150 mM) was
combined with 6 uL of PEI stock in tube 1 and 10 uL NaCl (150 mM) and siRNA against
the GR (2 ug) (Santacruz; sc-35505) in tube 2. Scrambled siRNA (Sigma, sc-37007) was
used as control (2 ug/well). Each tube was incubated at room temperature for 10 minutes
and then combined and incubated for an additional 10 min. at room temperature. The
transfection reagents were then added to each well drop-wise and incubated for 12 hrs.
upon which Cortisol (40 uM) or DMSO control was added. 12 hours. Post-treatment with
Cortisol or DMSO cells were removed via trypsinization and a 50 uL sample was used for
cell proliferation assessment utilizing the trypan blue exclusion assay as described above.
The remainder of the sample was used for total RNA extraction and converted to cDNA
as described below. RT-PCR was performed to confirm GR knockdown as described
below.
RT-PCR.
Total RNA was extracted using RNeasy Plus (Qiagen). RNA quality and quantity were
analyzed using the RNA 6000 Nano Assay and 2100 Bioanalyzer (Agilent). For endpoint
RT-PCR, reverse transcription was carried out using Superscript ™ II Reverse
Transcriptase (Invitrogen). Taq PCR (Qiagen) was used for all PCR reactions. All primers
were designed using the program Primer Express, and were generated (Sigma) to span
exon-exon

junctions:

Human

CAGCATGCCGCTATCGAAA-

GR
3",

(hGR)

forward

reverse

primer

primer

(A201)
(A202)

5'5"-

TAGTGGCCTGCTGAATTCCTT- 3' Human GAPDH (hGAPDH) forward primer
(A087) 5'- GCACCGTCAAGGCTGAGAAC-

3', reverse primer

(A088) 5'-

GGATCTCGCTCCTGGAAGATG-3' Human GAPDH was used as control. PCR cycles
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were optimized to ensure that end-point measures were on a log-phase scale, in all blots
shown 27 amplification cycles were used. All PCR products were separated on 8%
polyacrylamide gel electrophoresis. Gels were visualized on an Alpha Innotech HD2 Gel
Documentation System after ethidium bromide staining for 15 minutes using
AlphaEaseFC Software.
Q-RT-PCR was carried out using primer/probe sets from ABI; hFRYL
(Hs01102973_ml) and endogenous control 18S (Hs99999901_sl). For assessment of the
gene FRYL in breast cancer lines, mRNA and cDNA were extracted, as described above,
cDNA was added to a specified well in a 96-well Optical Reaction Plate (code 128)
(ABI). Assessment of the gene FRYL in breast cancer tissue was performed using Human
Breast Cancer TissueScan Real-Time plates (BCRT501; OriGene). In both cases, taqman
gene expression master mixes as well as the primer/probe sets were used according to the
manufacturer's instruction (ABI). Real Time PCR was performed according to the
specification and recommendations from ABI. Q-RT-PCR was done in triplicate, and fold
expression values (RQ) were calculated against the normalized control.
Microarray.
HTB-26 cells were plated onto 10 cm plates at 8x10^ per 8 mis of serum-filled media
per plate and allowed to adhere for 24 hours. Cortisol or DMSO control was added and
allowed to incubate for 0 and 12 hours. Upon time-point completion, cells were
trypsinized and total RNA was extracted using the RNeasy Plus Kit (Qiagen). RNA
quality and quantity were analyzed using the RNA 6000 Nano Assay and 2100
Bioanalyzer (Agilent). RNA was packed in dry ice and shipped to the University Health
Network microarray facility (Toronto, Ontario, Canada). RNA was converted into cDNA
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where Cortisol and DMSO control treatment cDNA was labelled with Cyanine dyes (Cy5
and Cy3 dye, respectively) (Amersham Biosciences). Hybridization of both cDNA
treatments to a 27K human gene array was then performed on the Advalytix
SlideBooster™ (Advalytix, Germany) utilizing DIG Easy Hyb hybridization solution.
Flip dye ratio was used as an internal control. The 27K human array chip was scanned on
the Agilent G2565BA scanner and quantified with ArrayVision v.8.0 (Imaging Research
Inc.). Data was analysed using the LOWESS method of normalization and then through
SAM (Statistical Analysis of Microarrays). Gene targets were initially selected based on
gene up or down regulation with a minimum of a 6 log increase or decrease. Further
screening of gene targets included criteria fitting novelty, relation to breast cancer, and
relation to cancer in general.
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RESULTS:
Cortisol Stimulates Proliferation in Subsets of Human Breast Cells.
Utilizing various cell lines trypan blue exclusion (Figure 1A, D, and E) and MTT assays
(Figure IB, and C) were performed using Cortisol or the vehicle control, DMSO.
Increased proliferation was seen in the human cancer cell line MCF7 as early as 4 hours
with statistical significance reached consistently for all doses post 4 hours (p<0.05)
(Figure 1A). Cell proliferation was seen in a dose responsive manner with 2.5 fold
increase cell numbers by 12 hours for 80uM. Cortisol stimulates highly invasive human
breast cancer cell lines HTB-26 (Figure IB) with statistical significance with the 10 and
20 uM concentrations (p< 0.01), as well as with the invasive breast cancer cell line HTB132 (p< 0.01) (Figure 1C). In Figure IE Cortisol treatment of the non-cancerous mouse
mammary cell line HC11, having a p53 mutation, did not show increased proliferation
within the early time points, but did significantly proliferate by time points 12 and 24 hr
(p< 0.01). These results were not found with respect to the non-cancerous human cell line
HTB-125 (Figure ID) where significance was not reached consistently throughout each
time point. Collectively, this data demonstrates that Cortisol enhances breast cancer cell
numbers and may render susceptibility to breast cells harbouring mutations in p53.
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Figure 1. Cortisol Stimulates Proliferation in Subsets of Human Breast Cells.
(A) Trypan blue analysis using MCF7 cells was performed in triplicate. Coloured lines
represent proliferation over time with various concentrations of Cortisol shown as lOuM
( •

), 20uM ( •

), 40uM ( •

), 80nM (

), or Control ( •

). Control

represents the vehicle that Cortisol was brought into solution, DMSO. Time was measured
in hours as shown on the X-axis, and number of cells counted is reflected on the Y-axis.
Results were verified using MTT analysis (MTT Replicated) (MTT Rep.).
(B) Proliferation of human invasive breast cancer cells, HTB-26 was studied using a MTT
assay performed in triplicate. Coloured bars represent proliferation with various
concentrations of Cortisol shown in the legend as 0.1 uM ( I
( •

), 20uM (

), Control ( •

), and NT ( •

), LOuM ( H

), lOuM

). Control represents DMSO

treated cells; No treatment (NT) represents cells lacking treatment with either Cortisol or
DMSO. Time was measured in hours, and proliferation was measured by absorbance at
590nm as shown on the X and Y axis, respectively.
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(C) Proliferation of human invasive breast cancer cells HTB-132 measured by MTT
assay, performed in triplicate. Coloured bars represent proliferation with various
concentrations of Cortisol shown as 0.1 uM ( I
(

), Control ( •

). 1.0uM( I

), 10uM( I ) , 20u.M

), and NT ( • ). Control represents cells treated with DMSO; NT

represents cells without treatment. Time was measured in hours, and proliferation was
measured by absorbance at 590nm as shown on the X and Y axis, respectively.
(D) Human breast cell line HTB-125 utilizing a trypan blue exclusion assay, performed in
triplicate and was replicated by MTT analysis. Coloured lines represent cellular
proliferation over time with various concentrations of Cortisol shown as 0.1 uM ( I ),
luM ( •

), lOuM (

), 20uM ( • ), Control ( • ), or NT ( % ). Control represents

the vehicle that Cortisol was brought into solution, DMSO whereas NT represents cells
untreated. Time was measured in hours as shown on the X axis, and number of cells
counted is reflected on the Y axis.
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(E) Normal mouse mammary cell line HC11 utilizing a trypan blue exclusion assay,
performed in triplicate and was MTT replicated. Coloured lines represent cellular
proliferation over time with various concentrations of Cortisol shown in the legend as
0.1uM( •

), luM( •

), 10uM( •

),20uM(

) Control ( •

),orNT

( 9 ). Control represents DMSO treated cells and NT represents untreated cells. Time
was measured in hours as shown on the X axis, and number of cells counted is reflected
on the Y axis. For all sections statistical analysis was performed using a 2-tailed T-Test
assuming equal variance with standard deviations used to represent error bars. Statistical
significance represents probability (p). Results were not considered significant if a p
value was more than 0.05.
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Cortisol Stimulates Migration in Human Breast Cancerous Cells.
To study the effects of Cortisol on breast cell migration a Cytoselect™ 24-Well
Cell Migration Assay (Cell Biolabs, CBA-100) assays were utilized. Figure 2
demonstrates that Cortisol stimulates migration towards a chemoattractant significantly at
both 10 uM and 20 uM concentrations (p<0.01) in the invasive human breast cancer cell
line FTTB-26 cells but failed to significantly aid in migration of the normal mouse
mammary HCll cell line (Figure 2A & B). Wound healing assays demonstrated similar
results where Cortisol concentrations ranging from 10- 80 uM stimulated migration, or
closing of a wound, in the human invasive breast cancer HTB-26 cell line (Figure 2C). As
early as 3 hours post wound infliction HTB-26 cells treated with Cortisol (80uM) revealed
migration capabilities reaching significance (p< 0.01). Statistical significance was
continuously met at 6, 12 and 24 hours (p< 0.05, and p< 0.01). By the end of the time
course HTB-26 cells treated with Cortisol stimulated migration, or closed the wound
compared to the DMSO control (80 uM) as well as the no treatment (NT) control.
However, wound healing of the normal mouse mammary cell line HCll treated with
Cortisol at various concentrations (10-80 uM) revealed no statistical significance
compared to the vehicle control (80 uM) as well as the NT control. Reaching statistical
significance (p< 0.01) at 24 hours the vehicle control and NT control were able to migrate
and close the wound, but not the Cortisol treated cells (Figure 2D). Collectively, these
data demonstrate that Cortisol aids the migration of cancerous breast cells as measured by
the ability move towards a chemoattractant as well as in the ability to repair a wound.
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Figure 2. Cortisol Stimulates Migration in Human Breast Cancerous Cells.
(A) Migration assays were performed using Cortisol at 20 uM and 40 uM and control,
DMSO, in HTB-26 cells. Purple staining indicates cells which have migrated through the
polycarbonate barrier (upper panels); the coloured bar graph reflects statistical analysis of
staining experiments carried out in triplicate with Control ( • ), 20 uM ( • ), and 40 uM
( • ) (lower panels). Control represents a DMSO vehicle control. Time was measured in
hours, and proliferation was measured by absorbance at 590 nm as shown on the X and Y
axis, respectively.
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(B) Migration assays were performed using Cortisol and vehicular control in HC11 cells.
Purple staining indicates cells which have migrated through the polycarbonate barrier
(upper panels); coloured bar graphs reflect statistical analysis of staining experiments
carried out in triplicate with Control ( • ), 20 uM ( • ) , and 40 uM ( • ) (lower panels).
Control represents the DMSO vehicle control. Time was measured in hours, and
proliferation was measured by absorbance at 590 nm as shown on the X and Y axis,
respectively.
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(C) Wound healing was performed utilizing HTB-26 cell line treated with Cortisol
concentrations of lOuM ( •

), 20uM ( • ), 40uM ( • ), 80uM (

), Control

( I ) , and NT ( • ) and was performed in triplicate. Control represents a DMSO vehicle
control and NT represents cells untreated. Line graphs reflect migration of HTB-26 cells
to close a wound over time and how many grids the cells migrated as shown on the X and
Y axis, respectively. Visual observations were taken using the microscope software
minisee 1.0.9.37. Visual observations were quantified by super-imposing a control image
consisting of 1mm by 1 mm grids. Number of cells that migrated across to close the
wound was counted.
(D) Wound healing was performed utilizing HC11 cell line treated with Cortisol
concentrations of lOuM ( • ), 20uM ( • ), 40uM ( • ), 80uM (

), Control ( •

),

and NT ( • ) and was performed in triplicate. Control represents a DMSO vehicle control
and NT represents cells. Line graphs reflect migration of HC11 cells to close a wound
over time and how many grids the cells migrated as shown on the X and Y axis,
respectively. Visual observations were taken using the microscope software minisee
1.0.9.37 Visual observations were quantified by super-imposing a control image
consisting of 1 mm by 1mm grids. Number of cells that migrated across to close the
wound was counted. In all panels, errors bars reflect standard deviation with statistical
significance assessed using a 2-tailed T-Test assuming equal variance with probability
(p). Results were not considered significant if a p value was more than 0.05.
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Cortisol Stimulates Human Breast Cancerous Cells Throughout the Cell Cycle.
To determine whether Cortisol effects were reflecting changes at one specific point
in the cell division cycle, cells were monitored over a time course following Cortisol
treatment by flow cytometry. As seen in Figure 3 Cortisol treated cells stimulated the
human breast cancer MCF7 cell line continuously and significantly faster out of GO/Gl
(p< 0.01) as early as 4 hours post treatment compared to the vehicular control. By 24 hrs.
post-treatment Cortisol treated cells revealed a 40% reduction of cells in GO/Gl phase of
the cell cycle over control (Figure 3A). Similarly, Cortisol treated MCF7 cells continually
and significantly (p<0.01) increased the rate at which cells entered into G2/M phase of
the cell cycle as compared to vehicle control (Figure 3B). By 24 hrs post-treatment
Cortisol treated cells reveal a 23% increase in the G2/M cell population. Both cell
populations had approximately 20% of the cells in a sub-GO population indicative of
apoptosis following treatement. For the Cortisol treated cells an additional polyploidy
population was noted that was not included in this analysis. This data supports that
Cortisol enhances breast cancer cell progression through the cell cycle.
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Figure 3. Cortisol Stimulates Human Breast Cancerous Cells Throughout the Cell Cycle.
(A) Cell cycle analysis utilizing flow cytometry was performed on MCF7 cells treated
with 40 uM ( • ) or DMSO control ( • ) in triplicate. Line graph represents MCF7 cells
exiting G0/G1 phase of the cell cycle. Time was measured in hours as shown on the Xaxis,

and

percent

of

cells

assessed

is

reflected

on

the

Y-axis.

(B) Cell cycle analysis utilizing flow cytometry was performed on MCF7 cells treated
with 40 uM ( • ) or DMSO control ( • ). Line graph represents MCF7 cells entering
G2/M phase of the cell cycle. Time was measured in hours as shown on the X-axis, and
percent of cells assessed is reflected on the Y-axis. For both panels, statistical analysis
was performed using a 2-tailed T-Test assuming equal variance with standard deviations
used to represent error bars. Statistical significance represents probability (p). Results
were not considered significant if a p value was more than 0.05.
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Cortisol Effects Are Mediated through Glucocorticoid Receptor Signalling.
It is widely accepted that cortisol-mediated effects may be mediated through the
GR or via cross talk with other steroid receptors. To determine the role of these other
receptors on GR-mediated proliferation in breast cells we utilized pharmacological and
knockdown approaches. Utilizing the human breast cancer cell line MCF7, which are ER,
PR and GR positive, increasing concentrations of the GR/PR inhibitor, RU486 show
remarkable significant decreases (p< 0.01) in cell proliferation in the presence of Cortisol
where increasing concentrations of the ER inhibitor, TAM did not have any effect on
cellular proliferation in the presence of Cortisol (Figure 4A). This data demonstrates that
Cortisol is not mediating specific proliferative effects through the ER. To further analyze
the contribution of the GR to these proliferative effects the GR was knocked down in the
human invasive breast cancer cell line HTB-26, which are ER negative but and PR and
GR positive (Figure 4B). This was accomplished using specific siRNA or a scrambled
siRNA control and proliferation was assessed in the presence of Cortisol or vehicle
control. RT-PCR confirmed partial, but significant knock-down on the GR (p< 0.01)
compared to siRNA control through denso-spot analysis (Figure 4C). GAPDH was used
as a loading control and was not significantly different in siRNA against the GR and
siRNA control (p= 0.1822). These results demonstrate that knockdown of the GR
significantly decreased (p< 0.01) Cortisol"s proliferative effects compared to the control,
confirming Cortisol's effects are mediated through the GR (Figure 4B).
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Figure 4. Cortisol Effects Are Mediated through Glucocorticoid Receptor Signalling.
(A) TAM at 1 nm ( • ), 10 nm ( •

), and 100 nm (B ) were utilized as an oestrogen

receptor inhibitor as well as RU486 at concentration of 3 nm ( • ), 30 nm ( • ), and 60
nm ( H ), a glucocorticoid and progesterone receptor inhibitor were utilized in the
presence of Cortisol at 40 uM (

) or DMSO control ( • ) using the MCF7 cells. The

DMSO control was utilized for comparison against receptor inhibition to assess whether
proliferation was significant. Bar graph represents cellular proliferation in the presence of
a receptor inhibitor, and was assess using a trypan blue exclusion assay. Time was
measured in hours as shown on the X-axis, and number of cells counted is reflected on
the Y-axis. Statistical analysis reflects triplicate counts.
(B) Inhibition of the GR was done utilizing siRNA against the GR in the HTB-26 cell line
and was performed in triplicate. Bar graph represents cellular proliferation in the presence
of the siRNA against the GR ( •

), siRNA scrambled ( • ), and DMSO control

( • ). The vehicle control was utilized for comparison against siRNA against the GR as
well as the siScrambled to assess whether proliferation was still significant in the
siScrambled control. Cell proliferation was assessed using a trypan blue exclusion assay.
Time was measured in hours as shown on the X-axis, and number of cells counted is
reflected on the Y-axis.
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(C) RT-PCR was performed utilizing cDNA generated from the HTB-26 treated cells
from the siRNA against the GR and the siScrambled performed in triplicate. Human GR
is shown in the upper panel as hGR where hGAPDH represented loading control, human
GAPDH in the lower panel. Expression fold values were assessed using denso spot
analysis. For all panels, statistical analysis was performed using a 2-tailed T-Test
assuming equal variance with statistical significance represents probability (p). Results
were not considered significant if a p value was more than 0.05.
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Identification ofCortisol-Mediated Gene Expression in Invasive Human Breast Cancer
Cells.
There are a number of microarray studies currently conducted using DEX treatment, as
well as several using Cortisol treatment however there is no existing data for invasive
human breast cancer cells. Our data reflect that cell lines such as the HTB-26 respond
most drastically with regard to proliferation and migration in response to Cortisol.
Importantly, these cells are ER independent and therefore allow us to study the gene
expression effects of Cortisol in the absence of cross talk from the ER. HTB-26 cells
were treated with Cortisol at 40 uM, or a DMSO control and RNA was sent to the UHN
facility at the University of Toronto, Canada. Synthesis of cDNA was performed and
hybridized to a 27K human array chip, and performed in triplicate. SAM analysis
revealed a total of 624 significantly down-regulated genes, and 398 significantly upregulated genes were revealed for a total of 1,022 potential gene targets (A & B). All
potential gene targets were assessed and selected based on set criteria. In total, 24
significantly down-regulated (A) and 14 significantly up-regulated gene targets (B) were
selected for further analysis. Selection criterion was based on a minimal expression fold
log value of 6 followed by further selection for those targets exhibiting novelty, relation
to breast cancer, and relation to cancer in general.
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Table 1. Cortisol Influences Up-Regulated Gene Expression in Various Genes.
Represents genes that were significantly down-regulated by Cortisol at 40 uM compared
to the DMSO control. Expression fold value represents a log value of Cortisol treated
HTB-26 cells where expected expression fold value represents a log value of vehicular
control treated HTB-26 cells. Log values represent the exponent value with a base of 2.
such as gene Ovo-like 1 (Drosophilia) expression value is 2 ~l '5 " " Microarray gene
expression was performed in triplicate and statistical analysis was assessed via SAM.
Data was not considered significant if the log value was below 6.
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Table 1

Name of Gene Target

Expression Fold
Value

Expected Expression Fold
Value

Ovo-like l(Drosophila)
Protein tyrosine phosphatase, non-receptor type
21

-16.52595

0.48045823

-16.340612

0.45944917

RAP2B, member of RAS oncogene family

-16.18119

0.46842855

Glutamate receptor interacting protein 1

-15.769973

0.5296949

Mitogen-activated protein kinase kinase kinase 7

-14.718367

0.4430995

Tetraspanin 8

-14.269757

0.44092378

NLR family, pyrin domain containing 1

-14.00973

0.4729342

Glypican 4

-12.848505

0.4675239

Integrator complex subunit 6

-11.160135

0.43560275

P21 (CDKN1A)-activated kinase 2

-11.058357

0.6534912

Leucine rich repeat containing 61

-10.76905

-0.4869869

B-cell CLL/lymphoma 10
Killer cell lectin-like receptor subfamily C, member
2

-10.52266

0.43166247

-10.456471

0.4410412

Cyclin-dependent kinase 3

-10.409155

0.4648322

HSPB (heat shock 27kDa) associated protein 1

-10.202217

0.56796604

Growth arrest-specific 2

-9.612179

0.44288394

BH3 interacting domain death agonist

-9.232355

0.50470066

DNA-damage-inducible transcript 4

-9.009577

0.4942023

Kruppel-like factor 12
Tumor necrosis factor (ligand) superfamily,
member 8
Cyclin-dependent kinase inhibitor 2B (p15, inhibits
CDK4)

-8.8060055

1.7626563

-8.57361

0.4619426

-7.837138

0.44549263

Inhibitor of growth family, member 1

-6.747879

0.4268193

Jun D proto-oncogene
Fibroblast growth factor 7 (keratinocyte growth
factor)

-6.6851487

1.1614074

-6.2941537

1.8904877
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Table 2. Cortisol Influences Down-Regulated Gene Expression in Various Genes.
Represents genes that were significantly up-regulated by Cortisol at 40 uM compared to
the vehicle control, DMSO. Expression fold value represents a log value of Cortisol
treated HTB-26 cells where expected expression fold value represents a log value of
vehicular control treated HTB-26 cells. Log values represent the exponent value with a
base of 2, such as gene Metallothionein 2A expression value is 2

Statistical

analysis was assessed utilizing SAM. Data was not considered significant is the log value
was below 6.
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Table 2

Name of Gene Target

Expression Fold
Value

Expected Expression
Fold Value

Metallothionein 2A

22.425978

-0.14324372

Metallothionein IF

13.396568

-3.9294183

Metallothionein 1G
Growth factor independent 1 transcription
repressor

12.301996

0.31089145

10.780789

2.0504496

DENN/MADD domain containing 3
Transcription factor 7-like 2 (T-cell specific,
HMG-box)

10.189645

0.815617

10.01574

0.97176766

Aryl-hydrocarbon receptor repressor

9.644095

1.5719044

Metallothionein IE

8.898076

-1.0625384

Ras homolog gene family, member Q

8.528412

1.2853632

Protocadherin 8
BCL2/adenovirus ElB 19kDa interacting protein
1

7.5462537

0.58093745

7.1896663

1.521623

Dickkopf homolog 1 (Xenopus laevis)
Mitogen-activated protein kinase 8 interacting
protein 3
Cyclin-dependent kinase inhibitor 2C ( p l 8 ,
inhibits CDK4)

6.850006

2.9487922

6.7509437

0.65893143

Cyclin B2
Mitogen-activated protein kinase-activated
protein kinase 3

6.6810217

1.6156677

6.386154

1.9802139

6.104611

1.114327
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FRYL Gene Expression in Normal Mammary Development and Breast Cancer
Progression.
As part of a pilot microarray study utilizing a separate cell line a number of
interesting, unique genes were isolated which differed from those selected through the
HTB-26 array (data not shown). One of these targets was the FRYL gene, found to be 5
fold elevated when treated with 20 uM Cortisol for 12 hrs. Following up on this potential
target a differentiation time course was conducted using normal mouse mammary cell line
HC11 looking at FRYL expression levels utilizing RT-PCR followed by denso spot
analysis revealed a slight, but significant (p< 0.01, confluency day 4) up-regulation just
prior differentiation. During differentiation FRYL was found to be significantly downregulated through differentiation days 3-6 (p< 0.01, days 3 & 4; p< 0.05. day 6) (Figure
5A). Denso spot analysis revealed no significant difference for loading control.
mGAPDH. RT-PCR was performed in triplicate with denso spot analysis for statistical
purposes. Q-RT-PCR was then carried out to assess FRYL expression among a panel of
human breast cancer cell lines MCF7, HTB-26, and HTB-132 as well as the normal
human breast cell line MCF10-A treated with Cortisol, a DMSO control, or no treatment
(0 hr) (Figure 5B). This study revealed a significant log fold increase of 7 (p<0.01) in the
Cortisol treated human breast cancer cell line HTB-132, cells containing a p53 mutation.
Further analysis of the potential role of this gene in human breast cancers was conducted
using Q-RT-PCR analysis of a human breast cancer cDNA array (Figure 5C). This work
revealed FRYL to be up-regulated in the breast cancer stages 1 and 3A.
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Figure 5. FRYL Gene Expression in Normal Mammary Development and Breast
Cancer Progression.
(A) HCll cDNA assessing FRYL expression was performed utilizing RT-PCR. Upper
panel reflects mouse FRYL (mFRYL) expression levels throughout the differentiation
time course. Lower panel reflects mouse GAPDH (mGAPDH) utilized as a loading
control. cDNA assessing FRYL expression was performed in triplicate with expression
fold values assessed using denso spot analysis. Statistical significance was determined
using a 2-tailed T-Test assuming equal variance. Statistical significance represents
probability (p). Results were not considered significant if a p value was more than 0.05.
(B) Q-RT-PCR assessed FRYL expression in cell lines MCF-10A (
(

• ) . HTB-26(

• ), and HTB-132 (

!l • ). MCF7

• ) . Coloured bars represent the

various cell lines used where variation of colour shading reflect specific treatments for
each cell such that 0 hr represents no treatment, DMSO control, and Cortisol at 40 uM.
The Y axis reflects fold expression. Q-RT-PCR was performed in triplicate including a
loading control, 18s. Raw values were normalized to MCF-10A 0 hr with statistical
analysis performed using a 2-tailed T-Test assuming equal variance with standard
deviations used as error bars. Statistical significance reflects experiment in triplicate
where probability (p) is shown. Results were not considered significant if a p value was
more than 0.05.
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(C) Q-RT-PCR assessing FRYL expression in various breast cancer stages was
performed utilizing a human breast cancer tissue panel array. Coloured bars represent
various stages of breast cancer development at stage 0 ( I ) , 1 (
( I

) 3A ( I

), 2 A ( • ), 2B

) and 3C ( H ) with the Y axis reflecting fold expression of FRYL.

Raw values were normalized to a stage 0 breast tissue sample, and breast cancer tissue
samples were normalized utilizing p-actin by Origene.
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DISCUSSION:
This project focuses on the molecular mechanisms of Cortisol's potential role in breast
cancer initiation and progression. It was hypothesized that Cortisol functions through the
glucocorticoid receptor to mediate effects on cell growth, adhesion and migration
properties in both normal and cancerous breast cells. Specific aims of this project were to
determine the effects of Cortisol on: cell proliferation in normal and cancerous breast cells
as well as migration and invasion in cancerous breast cells, and the pathway of Cortisol's
mediated function in breast cancerous cell lines.
We demonstrate that stimulation with physiological levels of Cortisol directly
enhances breast cancer cell numbers compared to normal breast cells. The human breast
cancer cell line MCF7 (Figure 1A) revealed that Cortisol increased proliferation as early
as 4 hrs and continued to significantly stimulate proliferation (p< 0.05) throughout the
time course compared to the normal human breast cell line HTB-125 (Figure ID), as well
as the normal mouse mammary cell line HC11 (Figure IE). It was revealed that at later
time points, 12 and 24 hours, HC11 cells treated with Cortisol were able to reach
significant proliferation values compared to control. Although considered "normal*' the
HC11 cell line does have a p53 mutation which increases the probability that over time
this cell line will become cancerous. Furthermore, it was demonstrated that both human
invasive cancer cell lines HTB-26 and HTB-132 were significantly stimulated by Cortisol.
Despite showing similar proliferation patterns, when comparing the HTB-26 line to the
HTB-132 line, the -132 line showed more significant cellular proliferation at the 20 uM
(p< 0.0198) stimulated by Cortisol. One of the differences between these 2 invasive cell
-61-

lines is that the HTB-132 cell line has a mutated p53 whereas HTB-26 has normal p53
expression. These data support that p53 status may confer sensitivity to cortisol-mediated
proliferative effects; while interesting and potentially significant clinically this hypothesis
requires further investigation.
Cell migration and invasion are key components to metastatic breast cancer (Sliva,
2004). Metastatic cancers are known to have reduced levels of "metastasis suppressor
genes' (Moutsatsou and Papavassiliou, 2008) and drug targets are currently under
development as part of novel breast cancer treatment strategies (MacDonald, Freije,
Stracke, Manrow, & Steeg, 1996). Recently, Ouatas, Halverson, and Steeg, (2002)
demonstrated that DEX stimulates expression of Nm23-Hl and Nm23-H2; two genes
known to be highly expressed in metastatic breast cancer. Ouatas et al. (2002) also
showed that this increased expression level was through a GRE-dependent transcriptional
mechanism. High levels of Cortisol have been found in patients with adrenal, lung, and
bone metastasis (Palesh et al., 2007). Patients with metastatic breast cancer show higher,
flatter Cortisol rates in addition to decreased survival rates (Spiegel et al., 2006).
Furthermore, it has been shown that glucocorticoid supplements significantly increase
metastasis, in vivo (Herr and Buchler, 2006; Herr and Marme, 2005).
Cortisol levels have been known to increase invasiveness in ovarian cancer (Sood et
al., 2006), but little is known about Cortisol and invasiveness in general. Given the
previous literature surrounding Cortisol and metastasis we felt it important to assess
Cortisol's potential effects on migration and invasion. Utilizing a migration assay, it was
shown that Cortisol significantly (p< 0.01) enhances breast cancerous cell migration of the
-62

invasive human breast cancer cell line HTB- 26 (Figure 2A) as measured by the ability to
migrate towards a chemoattractant compared to normal mammary mouse cell line, HC11
(Figure 2B). Invasion was measured by wound healing assays measuring the ability to
invade an open space, or repair a wound. Cortisol stimulated the human invasive breast
cancer cell line HTB-26 (Figure 2C) to repair the wound compared to control whereas
Cortisol did not stimulate the normal mammary mouse cell line HC11 (Figure 2D). This
supports the proliferation studies to suggest that Cortisol has differential effects on cells of
varying growth status. 'Normal' cells with intact checkpoints appear to prevent Cortisol
effects for the limited time course tested, whether these results would differ if
experiments were carried out over a longer period of time remains to be determined. The
effects of Cortisol on breast cancer cells is not only important for the physiological
relevance reflecting the potential adverse results of a stress, but clinically these results are
important since they can help to reconcile the studies utilizing DEX. DEX treatment has
revealed both positive and negative effects on breast cell growth (van den Berg, Claffie,
Boylan, McKillen, Lynch, & McKibben, 1996; Ryde, Nicholls, & Dowsett, 1992,
respectively). Although a synthetic of Cortisol, DEX is structurally different from Cortisol
such that it has fluorine off of carbon 9, and is considered to be 20-30 times more potent
than Cortisol (Zoorob, and Cender, 1998). Considering Cortisol is known to produce
different effects throughout the body, and at different physiological concentrations, the
higher potency of DEX relative to Cortisol that the observations made with DEX are not
an accurate interpretation or even assumption that Cortisol would behave similarly. This
holds tremendous implications for clinical treatment with respect to breast cancer.
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Cell cycle analysis revealed Cortisol significantly increases the rate that cells exit
from Gl phase of the cell cycle as early as 4hrs (p< 0.01), and continues to stimulate the
cell significantly throughout the cell cycle into G2/M as early as 2 hrs (p<0.01). It has
been shown that many breast cancer cells over-express Gl/S cyclins such as cyclin E
(Barton, Akli, & Keyomarsi, 2006) at the mRNA and protein levels (Keyomarsi, Conte,
Toyofuku, & Fox, 1995). It is known that cyclin E has different isoforms, one of which is
a "post-translational cleavage" of the full-length cyclin E into a lower molecular weight
(LMW) and reveals a more active protein than the full-length cyclin E. These altered
cyclin E proteins are unique to tumour cells in addition to being associated with stages of
breast cancer (Barton et ah, 2006). Keyomarsi et ah (2002) assessed cyclin E levels in
breast cancer tumour samples from 395 women to examine if there was a correlation of
cyclin E with these breast tumours. Their results demonstrate that both the full length and
shorter length sequence of cyclin E were present: they concluded that cyclin E is a very
strong predictor of cancer survival through breast cancer stages 1 to 3. Furthermore,
Matsumoto and Mailer (2004) demonstrated that this short isoforms version of cyclin E is
functional and over-expressing this isoforms in normal cells stimulate them to move into
S phase and even G2/M phase of the cell cycle. Given Cortisol's ability to stimulate
cancerous cells out of G0/G1 and into S phase future project objectives include assessing
Cortisol's possible interaction with cyclin E. Protein analysis looking at cell cycle
regulators such as cyclin E and D would be valuable to address specific areas within the
cell cycle Cortisol is mediating its effects. Further work includes looking into the CDKs 2,
4 and 6, as well as the CDKIs. These future project objectives will help to narrow where
specifically Cortisol is interacting within the cell cycle, and with what partners.
-64-

Interestingly, Dr. Porter pulled out numerous proteins in a yeast 2 hybrid screen (data
unpublished) but did not pull out cyclin E. Future work includes looking at the different
isoforms of cyclin E with Cortisol to investigate if 1 or more isoforms interact with
Cortisol as this would help to explain the observed transition through Gl/S. Furthermore,
cyclin B did come up in the yeast 2 hybrid screen; which is consistent with a larger
population of cells in G2/M (Wang, Fu, Mani, Wadler, Senderowicz, & Pestell, 2001).
Glucocorticoids are known to interact with multiple steroid receptors and demonstrate
steroid cross-talk capability (Moutsatsou and Papavassiliou, 2008). Thus it was
imperative to determine which steroid receptor was mediating Cortisol's effects through.
Receptor inhibition using TAM revealed that Cortisol is working through either the PR or
GR, or both, and not the ER (Figure 4A). Selective knockdown using siRNA against the
GR was utilized to determine whether the effects observed were indeed mediated through
the GR. Cortisol's effects are working through the GR: a trypan blue exclusion assay
demonstrates a significance decrease (p< 0.01) in proliferation compared to the siRNA
control (Figure 4B), and was now no longer significant compared to the vechicle control
(p=0.284). Although the siRNA against the GR only partially knocked-down the receptor
(Figure 4C) denso spot analysis confirmed a significant decrease in GR levels (p<0.01)
whereas all GAPDH levels did not significantly differ (p= 0.1822). Statistical analysis
comparing proliferation numbers with all RU486 concentrations against the proliferation
number for the siRNA against the GR revealed no significance difference (p= 0.0624; p=
0.279; p= 0.935, respective to RU486 concentration) thus confirming that cortisolmediated proliferation effects on the cell lines tested is solely interacting through the GR.
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Cortisol is known to target numerous genes revealing genomic and non-genomic
effects (Buckingham, 2006). However, which genes are affected and by what degree is
highly dependent upon where Cortisol is in the body (Moutsatsou and Papavasiliou,
2008). Microarray analysis has revealed numerous putative targets that could explain the
effects of Cortisol observed in these cancerous cell lines. Many interesting genes were
found to be significantly down-regulated. Protein tyrosine phosphatase, non receptor 21 is
known to be involved in several cell processes such as growth, cell cycle, and being
linked to oncogenesis (Liu, Kulp, Sugimoto, Jiang, Chang, & Li, 2002). Kruppel-like
factor 12 is also known to be involved in carcinogenesis (Tong, Czerwenka, Heinze,
Ryffel, Schuster. Witt, Leodolter, & Zeillinger, 2006). Tetraspanin 8 is also in cellular
processes such as development, and has been known to be linked to several cancers
(Carloni, Mazzocca, & Ravichandran, 2004). The NLR family, pyrin domain containing 1
are known to be highly involved in apoptosis (Franchi and Nuriez, 2008). Another gene
found to be down-regulated that is involved in apoptosis is the Inhibitor of growth
Family, Member 1 and has also been shown to be down-regulated in numerous cancers
(Hara et al., 2003) as well as being involved in the p53 signalling pathway. In addition to
this, protein BH3 interacting domain death agonist is also involved in apoptosis (Mebratu,
Dickey, Evans, & Tesfaigzi, 2008). Integrator complex subunit 6 is thought to be a
potential tumour suppressor (Hata and Nakayama, 2007). A very interesting potential
gene of interest is p21 (CDKN1A)- activated kinase 2 which is an important gene
encoding for a CDKI, and helps in cell cycle development in the Gl phase. This gene is
dependent upon p53, and helps with cell cycle cessation in the event of DNA damage
(Roy, Singh, Agarwal, Siriwardana, Schafani, & Agarwal, 2008). The Leucine rich repeat
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containing 61 gene is part of a family that is known to be down-regulated in breast cancer
(De Souza Santos, Bessa, Netto, & Nagi, 2008).
Several significantly up-regulated genes were also selected such as metallothionein
(MT) 2A, 1G and IF Although little is known about 1G; there are multiple reports focus
on 2A and IF and their link to breast cancer. MT-2A expression levels have been shown
to be positively correlated with increase cancer cell numbers (Jin, Chow, & Tan, 2002) in
addition to being associated with increased mortality rates among breast cancer patients
(Jin, Huang, Tan, & Bay, 2004). Abdel-Mageed and Agrawal (1997) also demonstrated
that the breast cancer cell line, MCF7, when over-expressed with MT-2A demonstrated
increase in proliferation. Another exciting gene target is Growth Factor Independent 1
Transcription Repressor which encodes for a transcriptional repressor protein and is
known to play a role in oncogenesis (Person, Li, Duan, Benson, Wechsler, Papadaki,
Eliopoulos, Bertolone, Nakamoto, Papayannopoulou, Grimes, & Horwitz, 2003). Another
interesting up-regulated gene target is protocadherin 8 which is known to be involved in
cellular adhesion. Cellular adhesion is also known to be a key component to invasiveness
(Yu, Koujak, Nagase, Li, Su, Wang, Keniry, Memeo, Rojtman, Mansukhani, Hibshoosh,
Tycko, & Parsons, 2008).
Future project directions include primer design for all selected targets. Cell line HTB26 will be counted, and seeded as described previously, treated with Cortisol or the
appropriate control, and allowed to incubate for 12 hours. Following incubation, cells
with be lysed, RNA extracted and cDNA synthesized. Confirmation of gene targets will
include RT-PCR with cDNA from the HTB-26 experimental cells. Upon confirmation,
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gene targets will be assessed to see if they are essential or sufficient for Cortisol mediated
proliferation through selective knock-down using shRNA contracts expressed in the
pSHAGl plasmid as well as over-expression of the gene target by shuttling the cDNA
into pLENTI4, both of these constructs are gateway plasmids that allow the option of
recombining into a lenti-viral vector. Upon successful cloning into the knock-down vector
pSHAGl and over-expression vector pLENTT-4, any cell line can be infected and effects
on cell proliferation, migration, gene expression and cell cycle progression will be
performed.
The human gene fury (FRYL), originally described in drosophila, is known to be
involved in ensuring the polarized cell extensions remain intact. FRYL is also thought to
be involved in controlling the actin cytoskeleton, and may even work to activate
transcription (The Universal Protein Resource (UniProt)). It is highly conserved which is
thought to be indicative of gross selective pressures to sustain the region that is essential
for protein function (Hayette, Cornillet-Lefebvre, Tigaud, Struski, Forissier. Berchet,
Doll, Gillot, Brahim, Delabesse, Magaud, & Rimokh, 2005). Its homolog among yeast
and C. elegans have been identified as being imperative for the proper functioning of the
Ndr family of AGC kinases; which are known to be crucial regulators of the cell cycle as
well as morphogenesis (He, Fang, Emoto, Jan, & Adler, 2005; Tamaskovic, Bichsel. &
Hemmings, 2003). Although FRYL in humans remains elusive, it is most commonly
associated with myeloid lymphatic leukemia, or mixed lineage leukemia (MLL) as a
fusion partner (Hayette et al., 2005). Three case studies looking at MLL have reported
reciprocal chromosomal translocations between the MLL gene and the FRYL gene. 2 of
which presented cases of breast cancer. Hayette et al. (2005) were the first to identify
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FRYL as a novel fusion partner with the MLL gene. They reported a case study of a 67year old female who was previously diagnosed with breast adenocarcinoma, and then was
diagnosed as suffering from 'therapy-related acute lymphoblastic leukemia (ALL)' Sait,
Claydon, Conroy, Nowak, Barcos, and Baer (2007) reported a case of a 49-year old
female who was originally diagnosed with acute lymphocytic lymphoma, but then rediagnosed a year later with multifocal invasive ductal carcinoma which was negative for
ER and the PR.
Denso-spot analysis revealed a slight increase in gene expression from proliferation
day 1 to confluency day 4 with statistical significance found for confluency day 4 (p<
0.01) and then was down-regulated during the differentiation stages with statistical
significance being met for differencial days 3, 4, and 6 (p< 0.01 for days 3 and 4; p< 0.05
for day 6) of the differentiation time course and not during the proliferative stages of
HC11 cell line suggesting (Figure 6A) that in normal development, FRYL levels remain
constant up until differentiation where it becomes down-regulated. Quantitative RealTime PCR analysis revealed FRYL to be significantly up-regulated (p< 0.01) in the
invasive breast cancer cell line HTB-132 compared to all other breast cancer cell lines as
well as the normal human breast cell line MCF10-A (Figure 6B). As stated earlier,
invasive cell line HTB-132 harbour a p53 mutation. Interestingly, Wiederschain, Kawai,
Shilatifard, and Yuan (2005) demonstrated that many of the MLL fusion proteins, such as
FRYL, actually are capable of preventing p53 activity even when the fusion proteins were
expressed at low levels; which is thought to possible explain chemotherapy resistance.
Barlev, Liu, Chehab, Mansfield, Harris, Halazonetis, and Berger (2001) have even
implicated MLL fusion partners, such as FRYL, are directly linked to changing normal
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bone marrow cells into leukemias among animal models. Assessing the potential
implications of FRYL in human breast cancer using the cDNA array in Figure 6C
revealed interesting preliminary data where FRYL appears to be low during stage 0 of
breast cancer then increases expression nearly 3 fold in stage 1 then showing slight
decline in stages 2A and B, only to increase 2 fold in the early phases of stage 3. This
could potentially indicate that early expression of this protein is implicated in initiation of
specific forms of breast cancer. To date, no link between FRYL and breast cancer have
been eluded, but the association between p53 and FRYL warrants further investigation.
The preliminary data shown here suggests that FRYL is down-regulated in normal
mammary development up until differentiation, but is severely up-regulated in the
invasive cell line HTB-132 with a p53 mutation. Because the other cancer cell lines do
not have this p53 mutation perhaps wild-type p53 prevents inappropriate expression of
FRYL and thereby preventing potentially adverse effects mediated by this event. This
association requires further investigation.
Our data demonstrates that stimulation with physiological levels of Cortisol directly
enhances breast cancer cell numbers and increases the rate that cells exit from Gl phase
of the cell cycle. Furthermore, we have demonstrated that Cortisol enhances breast cancer
cell migration as measured by the ability to repair a wound as well as cell migration
towards a chemoattractant. Microarray analysis has revealed a number of very interesting
putative targets for these effects. We have begun confirmation of these selected targets
utilizing RT-PCR. Furthermore, from a previous microarray study we have identified a
potential novel gene, FRYL, which could be interacting with p53. To date, FRYL has not
been linked to breast cancer, and could be an important breast cancer marker.
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This unique approach to the study of tumourigenesis will play an important role in the
understanding an individual's risk of breast cancer and may reveal novel biomarkers that
ultimately lead to earlier diagnosis of breast cancer. Additionally, these pathways may
provide targets for drug design that will improve current treatment strategies after
diagnosis. Future work includes assessing these potential gene targets for their importance
of these identified targets to determine if they are essential or sufficient for Cortisol
mediated proliferation. Collectively, this work holds tremendous promise for improving
the treatment, long-term remission and quality of life for patients with breast cancer.
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